Watch Ticker

Apellis Pharmaceuticals, Inc. Common Stock

Go to Apellis Pharmaceuticals, Inc. Common Stock Website

$24.26

0.00 (0.00%)

Live

Previous Close

$24.26

Day Range

$0 - $0

Previous Day Range

$22.89 - $24.32

Market Cap

$2.9 billion USD

Day Vol.

Previous Day Vol.

3.4 million

Currency

USD

Primary Exchange

Nasdaq

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement s...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Apellis Pharmaceuticals, Inc. - FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

The FDA approved EMPAVELI® (pegcetacoplan) as the first treatment for rare kidney diseases C3G and primary IC-MPGN in patients 12 and older, demonstrating a 68% reduction in proteinuria and stabilization of kidney function in clinical trials.

Related tickers: APLS.

Read Full Article

Delveinsight - Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types

The age-related macular degeneration (AMD) market is expected to grow due to the launch of new therapies and increased healthcare spending. Dry AMD and wet AMD are the two main types, with new treatments in development for both.

Related tickers: APLS, ALPMY, CLSD.

Read Full Article

Trending Tickers

Please sign in to view